Dalrada Continues Upward Trajectory With 252% Growth in Third Quarter 2022 Financial Results
Dalrada Corporation (OTCQB: DFCO) reported record financial growth for Q3 2022, achieving revenue of $5,592,150, a 252% increase from Q3 2021's $1,588,329. For nine months, revenue reached $15,641,766, up 458% year-over-year. The surge is primarily due to the COVID-19 testing segment and the sale of Likido® products. The company signed five contracts under its new Dalrada Energy Services division, promising further revenue growth. Major accomplishments include validation of Likido®ONE heat pumps by U.S. authorities and expansion in sales, positioning Dalrada for ongoing success.
- Revenue of $5,592,150 in Q3 2022, up 252% year-over-year.
- Nine-month revenue total of $15,641,766, representing a 458% increase.
- Signing of five contracts in Dalrada Energy Services, set to enhance revenue.
- Validation of Likido®ONE heat pumps by U.S. agencies supports market credibility.
- None.
During the quarter ending
Dalrada has completed multiple contracts related to Dalrada Energy Services and anticipates revenue to arrive within a short period of time. Additionally, Dalrada is actively managing significant opportunities outside its core businesses and expects further increased revenues and shareholder value during the remainder of the fiscal year.
Dalrada's agility allows it to respond immediately to demands for safer alternative products and services that provide significant value and benefit.
In the third quarter alone, Dalrada's major accomplishments included:
-
Field validation of Likido®ONE heat pumps by the
U.S. General Services Administration andDepartment of Energy's Green Proving Ground program for use in federal buildings to accelerateU.S. net-zero sustainability initiatives that reduce reliance on carbon-emitting fossil fuels. TheU.S. GSA's real estate portfolio spans more than 8,800 assets, including more than 500 historic properties, and manages almost 370 million square feet of rentable workspace for more than a million federal employees. -
Dalrada Health completed the second clinical trial of its cerVIA™ visual inspection with acetic acid (VIA) standardized test kits inIndia , providing an accessible alternative to traditional cytology diagnostic tests for cervical cancer screening and prevention that are unavailable in low to middle-income countries. - Domestic and international sales expansion.
- Increased availability of portfolio products and services.
- Expansion of Dalrada's Board of Directors and Advisory Boards with renowned industry leaders whose influence impacts clean energy, healthcare, and technology market expansion – both domestically and internationally.
For additional information on Dalrada and its subsidiaries, visit www.dalrada.com.
About Dalrada (DFCO)
The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada's global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.
Established in 1982, Dalrada has since grown its footprint to include the unique business divisions:
Disclaimer
Statements in this press release that are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005406/en/
858.283.1253
inquiries@dalrada.com
Source:
FAQ
What was Dalrada Corporation's revenue for Q3 2022?
How much has Dalrada's revenue grown compared to Q3 2021?
What factors contributed to Dalrada's revenue increase?
What contracts did Dalrada Energy Services sign?